The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•26 February 2026•

1 min read

Biomerica Reports Positive IBS Therapy Data and Confirms Medicare Reimbursement Rate

Canadian flag, a plasma bag, and "GRIFOLS" text on an orange background with medical equipment, microscopes, and vials.

Key Facts

1Real-world data showed 59.4% of IBS patients achieved a 30% or greater reduction in abdominal pain using inFoods therapy.

Biomerica (BMRA) has announced positive real-world clinical data for its inFoods IBS therapy, marking a significant milestone for the company's clinical validation. The data revealed that 59.4% of patients experienced a reduction of 30% or more in abdominal pain, demonstrating strong efficacy. Additionally, 68.1% of participants reported a similar improvement in bloating, meeting key endpoints recognized by the FDA. Parallel to these clinical results, the Centers for Medicare & Medicaid Services (CMS) established a national payment rate of $300 for the therapy. This reimbursement rate is scheduled to take effect on January 1, 2026, providing a clear path for commercial scaling and revenue generation. Analysts view these developments as a major boost for the biotech firm's market confidence and future growth prospects.